BR112017011642A2 - composto, sal farmaceuticamente aceitável, e, método para tratamento de uma doença ou condição que se beneficia de um aumento em nad+. - Google Patents

composto, sal farmaceuticamente aceitável, e, método para tratamento de uma doença ou condição que se beneficia de um aumento em nad+.

Info

Publication number
BR112017011642A2
BR112017011642A2 BR112017011642A BR112017011642A BR112017011642A2 BR 112017011642 A2 BR112017011642 A2 BR 112017011642A2 BR 112017011642 A BR112017011642 A BR 112017011642A BR 112017011642 A BR112017011642 A BR 112017011642A BR 112017011642 A2 BR112017011642 A2 BR 112017011642A2
Authority
BR
Brazil
Prior art keywords
nad
treating
benefits
disease
compound
Prior art date
Application number
BR112017011642A
Other languages
English (en)
Portuguese (pt)
Inventor
Richard Henke Brad
Schulte Christie
Haffner Curt
Norman Deaton David
PREUGSCHAT Frank
David Becherer J
Cadilla Rodolfo
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip No 2 Ltd filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of BR112017011642A2 publication Critical patent/BR112017011642A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR112017011642A 2014-12-03 2015-11-19 composto, sal farmaceuticamente aceitável, e, método para tratamento de uma doença ou condição que se beneficia de um aumento em nad+. BR112017011642A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462086844P 2014-12-03 2014-12-03
PCT/IB2015/058965 WO2016087975A1 (en) 2014-12-03 2015-11-19 Cd38 inhibitors and methods of treatment

Publications (1)

Publication Number Publication Date
BR112017011642A2 true BR112017011642A2 (pt) 2018-03-06

Family

ID=54708091

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017011642A BR112017011642A2 (pt) 2014-12-03 2015-11-19 composto, sal farmaceuticamente aceitável, e, método para tratamento de uma doença ou condição que se beneficia de um aumento em nad+.

Country Status (11)

Country Link
US (1) US9840496B2 (cg-RX-API-DMAC10.html)
EP (1) EP3227275B1 (cg-RX-API-DMAC10.html)
JP (1) JP6550132B2 (cg-RX-API-DMAC10.html)
KR (1) KR20170090478A (cg-RX-API-DMAC10.html)
CN (1) CN107428733A (cg-RX-API-DMAC10.html)
AU (1) AU2015356721B2 (cg-RX-API-DMAC10.html)
BR (1) BR112017011642A2 (cg-RX-API-DMAC10.html)
CA (1) CA2969178A1 (cg-RX-API-DMAC10.html)
ES (1) ES2717260T3 (cg-RX-API-DMAC10.html)
RU (1) RU2017121002A (cg-RX-API-DMAC10.html)
WO (1) WO2016087975A1 (cg-RX-API-DMAC10.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3544612A4 (en) 2016-11-23 2020-05-13 Acetylon Pharmaceuticals, Inc. PHARMACEUTICAL COMBINATIONS COMPRISING A HISTONE DEACETYLASE INHIBITOR AND A CD38 INHIBITOR AND METHODS OF USING THE SAME
WO2020146795A1 (en) 2019-01-11 2020-07-16 Omeros Corporation Methods and compositions for treating cancer
US11535621B2 (en) * 2019-07-31 2022-12-27 Ribon Therapeutics, Inc. Heterobicyclic amides as inhibitors of CD38
US20230025807A1 (en) * 2019-10-30 2023-01-26 Mitobridge Inc. Cd38 inhibitors
KR20230051425A (ko) * 2020-04-07 2023-04-18 미토브리지, 인크. Cd38 억제제
IL301991A (en) * 2020-10-09 2023-06-01 Napa Therapeutics Ltd Heteroaryl amide inhibitors for CD38
EP4263524A1 (en) 2020-12-21 2023-10-25 Cytokinetics, Inc. Pyrazole derivatives useful as nampt modulators
AR124718A1 (es) 2021-01-29 2023-04-26 Ribon Therapeutics Inc Quinolinas y azaquinolinas como inhibidores de cd38
EP4288053A4 (en) 2021-02-08 2024-12-18 Ohio State Innovation Foundation Small molecule inhibitors of cd38 as immunosuppressants
CN117715897A (zh) * 2021-04-30 2024-03-15 南京艾美斐生物医药科技有限公司 化合物及其作为cd38抑制剂的用途
US20230116972A1 (en) * 2021-07-12 2023-04-20 Cytokinetics, Inc. Cd38 modulators and methods of use thereof
EP4724430A1 (en) * 2023-06-07 2026-04-15 Flagship Pioneering Innovations VI, LLC Condensed azines as inhibitors of cyclic adp ribose hydrolase
WO2026000074A1 (en) * 2024-06-25 2026-01-02 Welnx Company Inc. Use of cd38 inhibitors for reducing th2 inflammation
WO2026075971A1 (en) 2024-10-01 2026-04-09 Neolaia Inc. Combination therapy for treatment of metabolic disorders and inflamation related disorders using incretin compounds and cd38 inhibitors
WO2026090190A1 (en) * 2024-10-22 2026-04-30 Aeovian Pharmaceuticals, Inc. Cd38 modulators and uses thereof
CN119775288B (zh) * 2024-12-31 2025-10-10 浙江工业大学 一种cd38抑制化合物及应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1370139A4 (en) * 2001-01-04 2010-09-22 Einstein Coll Med INHIBITORS OF ADP-RIBOSYLTRANSFERASES, CYCLASES AND HYDROLASES AND THEIR USE
US7022680B2 (en) * 2002-05-30 2006-04-04 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of ADP-ribosyl transferases, cyclases, and hydrolases
WO2010025235A1 (en) * 2008-08-29 2010-03-04 Regents Of The University Of Michigan Selective ligands for the dopamine 3 (d3) receptor and methods of using the same
EP2801573A1 (en) * 2013-05-09 2014-11-12 Sanofi Hydantoine derivatives as CD38 inhibitors

Also Published As

Publication number Publication date
US20170260164A1 (en) 2017-09-14
EP3227275A1 (en) 2017-10-11
WO2016087975A1 (en) 2016-06-09
RU2017121002A3 (cg-RX-API-DMAC10.html) 2019-03-15
ES2717260T3 (es) 2019-06-20
AU2015356721B2 (en) 2018-03-15
AU2015356721A1 (en) 2017-06-08
CA2969178A1 (en) 2016-06-09
RU2017121002A (ru) 2019-01-11
US9840496B2 (en) 2017-12-12
EP3227275B1 (en) 2019-01-02
CN107428733A (zh) 2017-12-01
JP2018501215A (ja) 2018-01-18
JP6550132B2 (ja) 2019-07-24
KR20170090478A (ko) 2017-08-07

Similar Documents

Publication Publication Date Title
PH12019501321A1 (en) Methods of treating or preventing cholesterol related disorders
ZA202001717B (en) Compounds, salts thereof and methods for treatment of diseases
BR112018004620A2 (pt) moduladores da expressão de kras
MX2021008281A (es) Estimuladores de guanilato ciclasa soluble (sgc).
CL2015003731A1 (es) Inhibidores de bromodominios
EA201891910A1 (ru) Гетероарильные ингибиторы pad4
PH12018501226A1 (en) Methods for treating huntingtons disease
EP4219718A3 (en) Compositions and methods for modulating complement factor b expression
MX2021009806A (es) Ésteres de ácidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y métodos para usar los mismos.
MX2017003516A (es) Derivados de pirazol como estimuladores de guanilato ciclasa soluble (sgc).
MX389228B (es) Composiciones para tratar el cabello.
EA201691134A1 (ru) Новые ингибиторы глутаминазы
EA201891251A1 (ru) Бициклические ингибиторы pad4
MX374452B (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
PH12019502174A1 (en) Modulators of pcsk9 expression
NZ748769A (en) Nitroxyl donors with improved therapeutic index
MX389591B (es) INHIBIDORES DE ACIDO A-AMINO-ß-CARBOXIMUCONICO SEMIALDEHIDO DESCARBOXILASA
MX370270B (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
BR112014026160A2 (pt) métodos para tratar intolerância à lactose
CL2017000484A1 (es) Compuestos de azetidiniloxifenilpirrolidina
MX388409B (es) Composiciones y metodos para tratar canceres.
MX2019004321A (es) Inhibidores de la acido alfa-amino-beta-carboximuconico semialdehido descarboxilasa.
MX2022006229A (es) Composiciones y metodos para el tratamiento de resistencia a la insulina.
BR112015023260A2 (pt) método de tratamento de grão com ozônio
WO2013188824A3 (en) Hexim-1 as a target of leptin signaling to regulate obesity and diabetes

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired